Unknown

Dataset Information

0

Thrombophilia Associated with Anti-DFS70 Autoantibodies.


ABSTRACT:

Context

Anti-DFS70 antibodies are the most frequent antinuclear antibodies (ANA) found in healthy individuals. We assessed the clinical significance of the presence of anti-DFS70 antibodies.

Methods

We defined a group of patients (n = 421) with anti-DFS70 antibodies and a group of patients (n = 63) with a history of idiopathic arterial and/or venous thrombotic disease and/or obstetric complication (i.e. ? 3 miscarriages, fetal death or premature birth with eclampsia). Anti-DFS70 antibodies prevalence was also assessed in a cohort of 300 healthy blood donors.

Results

The prevalence of thrombotic disease and/or obstetric complication in the 421 patients with anti-DFS70 antibodies was 13.1% (n = 55) and the prevalence of connective tissue disease was 19% (n = 80). Among the 63 patients with a history of thrombosis and/or obstetric complications, 7 (11.1%) had anti-DFS70 antibodies and among the latter, 5 had no common thrombophilic factor. In contrast, the prevalence of anti-DFS70 antibodies was of 3.0% (9 out of 300) in healthy donors. Finally, the Activated Partial Thromboplastin Time (aPTT) ratio of patients with a history of thrombosis and anti-DFS70 antibodies was lower than the aPTT ratio of other patients, suggesting that thrombotic patients with anti-DFS70 antibodies may have a hypercoagulable state.

Conclusion

We described here for the first time an immune procoagulant state involving anti-DFS70 antibodies.

SUBMITTER: Marlet J 

PROVIDER: S-EPMC4580612 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Context</h4>Anti-DFS70 antibodies are the most frequent antinuclear antibodies (ANA) found in healthy individuals. We assessed the clinical significance of the presence of anti-DFS70 antibodies.<h4>Methods</h4>We defined a group of patients (n = 421) with anti-DFS70 antibodies and a group of patients (n = 63) with a history of idiopathic arterial and/or venous thrombotic disease and/or obstetric complication (i.e. ≥ 3 miscarriages, fetal death or premature birth with eclampsia). Anti-DFS70 a  ...[more]

Similar Datasets

| S-EPMC5407719 | biostudies-literature
| S-EPMC1895668 | biostudies-literature
| S-EPMC5164872 | biostudies-literature
| S-EPMC5495341 | biostudies-literature
| S-EPMC6504697 | biostudies-literature
| S-EPMC8010366 | biostudies-literature
| S-EPMC7851666 | biostudies-literature
| S-EPMC3321746 | biostudies-literature
| S-EPMC507750 | biostudies-other
| S-EPMC7547497 | biostudies-literature